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Background: The purpose of this clinical study was to ascertain whether low molecular weight chitosan
polyglucosamine is able to produce significantly better weight loss than placebo.
Method: 115 participants were included in the study. We used a two-center randomized, double blind, placebo-
controlled design. The participants followed a standard treatment (ST), which included the combination of a low-calorie
diet achieved through creating a daily calorie deficit (500 cal) and an increased daily physical activity (7 MET-h/week).
They were randomized to receive standard treatment plus placebo (ST + PL) or standard treatment plus polyglucosamine
(ST + PG), respectively. Participants were instructed to take 2 × 2 tablets before the two meals containing the
highest fat content for at least 24 weeks. Body weight, BMI, waist circumference and the time needed for a 5 %
body weight reduction (5R) were taken as main variables.
Results: The average weight loss over a period of 25 weeks in the ITT population was 5.8 ± 4.09 kg in the ST + PG
group versus 4.0 ± 2.94 kg in the ST + PL (pU = 0.023; pt = 0.010). After 25 weeks, 34 participants achieved 5R in
the ST + PG group (64.1 %) compared to only 23 participants in the ST + PL group (42.6 %) (ITT) (p Fisher = 0.033).
Weight loss through hypo-caloric diets have been found to be effective. The additional effect of PG in
combination with standard treatment is able to produce significantly better weight loss than placebo.
Conclusions: Participants treated with ST + PG showed a significant amount of weight loss, an additional 1.8 kg,
compared to controls treated with ST + PL.
Trial registration: Trial Registration at ClinicalTrials.gov: NCT02410785 Registered 07 April 2015
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The prevalence of obesity in European countries has trebled
in the last 20 years [1] together with body weight increase.
Both events have a tremendous impact on quality of life and
are associated with numerous comorbidities such as cardio-
vascular diseases, diabetes mellitus and certain cancers.
The financial implication of these conditions is a cause
for concern since both direct and indirect costs of illness,
care and rehabilitation services will only grow larger over
time. Measures must be taken to reverse this upward* Correspondence: pokhis@mail.ru
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creativecommons.org/publicdomain/zero/1.0/trend and as yet, no gold standard has been established
for the treatment of overweight and obesity [2].
A guideline enabling practitioners and patients to
make decisions about appropriate treatment and health-
care for specific clinical conditions as well as taking into
account their personal circumstances, has been compiled
by different professional associations in Europe as well
as in Germany [3].
Additionally, medicines granted the marketing author-
isation by the European Medicine Agency (EMA) but
have failed to meet the expectations in their practical ap-
plication will be withdrawn from the market. As a result
of the increased risk of serious and sometimes fatalticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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authorisations for sibutramin and rimonabant across the
European Union [4,5]. Currently, orlistat is the only pre-
scription medicine available on the European market.
Some food and food supplements promise rapid and
effective weight loss in a relatively short period of time
without having to implement dietary and lifestyle
changes or additional physical activities.
However, weight management incorporating the use of
a medical device generally recommends implementing
healthy eating habits and making other lifestyle changes.
In order to promote compliance and enhance the effects
of the standard treatment, some therapists recommend the
use of the medical device polyglucosamine (PG). This prod-
uct works chemo-physically by binding to fat in the intes-
tinal lumen to form a complex partially used by colonic
bacteria as fuel and the remaining mass is eliminated [6,7].
As a result, the absorption of fat is inhibited and thereby im-
pairs the absorption of energy through dietary fat restriction.
This clinical study was conducted to assess the efficacy of
PG against placebo. Patients also made changes in behavior
patterns such as establishing healthy eating and exercise
habits in addition to taking the investigational product.
The evidence-based guideline “Prevention and Treat-
ment of Obesity” recommends making dietary changes
in terms of consuming a mildly hypocaloric diet provid-
ing a daily energy deficit of around 500 kcal which con-
tains approximately 30 % of fat [3].
However, the guideline in the current study was modi-
fied to include the additional intake of PG or placebo
and an increased intake of dietary fat from 40–60 g per
day to 60–80 g per day.
Methods
Study design
The study was conducted in two centers according to a
randomized, double-blind, placebo-controlled design
and in accordance with the requirements of the Direct-
ive 92/43/EEC and DIN EN ISO 14155-1 and in con-
formance with the provisions in the current version of
the Declaration of Helsinki. The Federal Data Protection
Act/Italian Personal Data Protection Code including
other applicable laws, regulations, mandatory standards
and commendations were also taken into consideration.
The patients were randomized to receive in addition to
standard treatment (ST) either PG or placebo, 2 x 2 tablets
before the daily meals containing the highest fat content.
The trial protocol was submitted to the relevant Ethics
Committee of the State Chambers of Physicians in Frank-
furt, Germany for evaluation, consideration and review
and given a favorable opinion before the study began.
In Italy, the trial protocol was sent for approval to the
Comune di Rende. The approval N14 was given according
to art. 48 del D. Lgs n 267/2000 at 28th January 2010.The patients in Germany were recruited into the clin-
ical trial from the surrounding area of Salztalklinik, Bad
Soden-Salmünster [Center 1] and the patients in Italy
were recruited during the MAP Study (Monitoraggio
Alimenti e Patologie) in the center of Rende, province of
Cosenza [Center 2].
Participants
Altogether 115 participants were included in the study,
36 of whom were men and 79 were women between the
ages of 21 to 75 years.
Inclusion criteria were as follows: BMI > 26 and < 45;
waist circumference of more than 88 cm for women and
greater than 102 cm for men.
Exclusion criteria were: pregnancy or breast-feeding; al-
cohol abuse, drug abuse or drug addiction; inability to ful-
fill the criteria of the trial protocol; cancer diseases,
malignant tumors; pre-existence of chronic intestinal dis-
ease and known hypersensitivity reactions to crustaceans.
Another exclusion criterion was the use of disease
modifying anti-diabetic drugs. Patients undergoing treat-
ment for chronic cardiovascular diseases were accepted,
provided no modification of the type of medication and
dosage regimen were undertaken during the trial.
Treatments
Each patient took 2 tablets of placebo or 850 mg of PG
twice daily before the two meals containing the highest
fat content.
PG consists of the combination of a 125–145 kD chi-
tosan (low molecular weight chitosan or LMWC) with
ascorbic acid and tartaric acid. The combination of these
substances forms a linear polymer [4,5] that is defined as
PG. Due to the fat binding capacity of the product, pa-
tients were instructed to take lipophilic medications of
at least four hours apart. As a preventive measure, at
least one meal should be taken with high-quality oils
(extra virgin) and fats to provide the body with fat-
soluble vitamins as well as essential fatty acids.
When the study started, weekly counseling and phys-
ical activity sessions were provided to the patients to
achieve an average 6–7 MET-h/week (daily cycling, aer-
obic dance, Nordic walking or swimming 2–3 times a
week). They also received a CD with information about
instructions regarding daily physical activity.
In order to achieve an energy deficit of 500 kcal/day,
all patients were advised to reduce their dietary fat in-
take by making changes to their diet according to the re-
quirements and recommended guidelines for foods to be
reduced or avoided.
Treatment began immediately after the enrollment
and each subject received 3 packs of 48 tablets (about
36 days of treatment). They were requested to return for
more product supply at the end of each month.
Enrolled and assessed for eligibility   (n = 115) 
Excluded (n = 8) 
  2 Only initial measurements 
  3 BMI < 26 kg/m2
  3 BMI > 45 kg/m2 
Standard Treatment + Placebo
            28 weeks intervention  (n = 54) 
Standard Treatment + Polyglucosamine 
           28 weeks intervention  (n = 53)    
Failed compliance
criteria             (n = 8)
Failed compliance
criteria             (n = 12)
Analyzed                   (n = 45) Analyzed                   (n = 42)
Fig. 1 CONSORT Statement Flow Chart of the enrolment and progress of participants through the phases of the study
Table 1 Characteristics of the patients at baseline (PP): average
(SD)
Variables Measure ST + PL group ST + PG group P U test
(N = 42) (N = 45) (t test)
Age Years 50.0 (8.91) 48.6 (8.67) 0.348 (0.469)
Height Cm 167.3 (6.70) 167.7 (7.63) 0.708 (0.806)
Weight Kg 97.9 (11.61) 98.4 (14.83) 0.884 (0.859)
Waist Cm 108.3 (9.86) 110.4 (10.13) 0.277 (0.335)
BMI kg/m2 35.0 (3.26) 35.0 (3.72) 0.758 (0.988)
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asked at every visit and documented.
After the enrollment (visit 0 as t0), 16 visits were com-
pleted during the study period of about 26 weeks (from
t1 to t16). The treatment started at visit t2 (baseline).
Sample size
The number of patients that was required to justify the
difference in weight loss between groups ST + PG and
ST + PL was determined based on the calculation ac-
cording to Cohen’s d with an effect size of 1.0. At a sig-
nificance level of 5 % with a statistical power of 80 %, 18
patients were required in each group as determined by
the Mann-Whitney-test according to the study protocol.
Considering a dropout rate of up to 20 %, the enroll-
ment target in each center was fixed to at least 23 cases
/ treatment group. All participants were informed that
they would be free to discontinue the study at any time
without giving any reason and without bearing any nega-
tive consequences.
Randomization
The random process using computer-generated block
randomization with a block size of four (program BiAS
Version 9.0) was not performed by a study staff but an
employee of Medizin & Service GmbH. It was imple-
mented by means of an allocation list. The study medi-
cations (verum and placebo) were packaged in blisters of
identical appearance by the manufacturer.
Patients were screened at visit 0 (week 0) to see if they
fulfilled the inclusion and exclusion criteria and the
baseline variables were taken again at the start of thetreatment. Compliance was measured by counting the
residual tablets. Patients not reaching at least 90 % of
the compliance rate were excluded from the evaluation.
The evaluation of compliance in relation to caloric re-
striction and physical exercise was not possible.
Statistical methods
The data were analyzed using both non-parametric (pri-
mary) and parametric (only explorative) statistics. The
averages and standard deviations were calculated for all
variables at the different times of observation. Differ-
ences in the time needed to achieve 5 % reduction of
body weight (5R) were measured according to Nonpara-
metric Survival Analysis (Kaplan-Meier) followed by the
log-rank test. At each visit, the differences in 5R were
measured according to Fisher’s exact test without cor-
rection for multiple testing.
Mann-Whitney-U test and (only exploratory) t test for
independent data were used to calculate the differences
between the variables pertaining to the two groups. The
differences between baseline value and the value at a
Table 2 Characteristics of the patients at baseline (ITT): average
(SD)
Variables Measure ST + PL group ST + PG group P U test
(N = 54) (N = 53) (t test)
Age Years 50.4 (9.38) 48.8 (9.80) 0.313 (0.391)
Height Cm 167.6 (6.24) 168.5 (8.02) 0.468 (0.519)
Weight Kg 99.5 (11.69) 99.8 (14.95) 0.923 (0.908)
Waist Cm 109.3 (10.14) 110.9 (10.55) 0.384 (0.431)
BMI kg/m2 35.4 (3.62) 35.1 (3.73) 0.533 (0.661)
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the two groups of treatment. Body weight reduction,
BMI, waist circumference and the time needed to
achieve 5R were taken as main variables. Due to the
small sample size, the non-parametric tests were per-
formed as exact tests.
Results
Exclusion from the clinical trial
Out of the 115 patients who gave their written informed
consent, a total of 28 patients were excluded from the
PP population due to the following reasons:
– Six patients had BMI values not in accordance with
the proposed criteria when the treatment started
(three patients had BMI values of less than 26 kg/m2
and three patients presented BMI values exceeding
45 kg/m2);
– Two patients attended only the inclusion visits; no
second measurement values were available;
These eight patients were excluded from the ITT
population, six patients with BMI values that did not
meet the inclusion criteria at visit t1 and a further two
patients where no efficacy data were available (discon-
tinuation of study after visit t1. Missing data as a result
of premature termination were carried forward with the
last available data in the ITT population.Table 3 Values of the anthropometric measures before and at the e
Times Body weight B
ST + PL ST + PG S
t2 97.9 (11.61) 98.4 (14.83) 3
t3 97.2 (11.33) 97.6 (14.55) 3
Changes shown as continuous variables
t15 93.7 (12.28) 92.2 (13.68) 3
t16 93.6 (12.28) 91.9 (13.70) 3
Weeks 26.1 (2.0) 25.6 (2.0)
Difference t16 from t2 4.3 (3.12) 6.5 (3.89)
p U test 0.008 0
p t test 0.005 0107 patients could be evaluated, 53 patients in group
ST + PL (27 patients in Center one and 26 patients in
Center two, respectively) and 54 patients in group ST +
PG (28 patients in Center one and 26 patients in Center
two, respectively).
20 patients did not meet the compliance requirements
after randomization (ST + PG; n = 8 = 40 %; ST + PL; n =
12 = 60 %).
87 patients treated per protocol could be evaluated, 42
in group ST + PL (22 in Center one and 20 in Center
two, respectively) and 45 subjects in group ST + PG (22
in Center 1 and 23 in Center two, respectively) Fig. 1.
During the first visits, a number of patients reported some
discomfort such as stomach ache and meteorism. Since
these symptoms were present in very few cases and in both
groups, they were considered possible side effects of the
early stages of making changes in diet. The complaints were
mild and temporary. During the first visits following the
treatment, four subjects treated with ST+ PG complained
of constipation, which disappeared in the following study
visits after increasing water intake. Three out of the four
subjects (Center 2) had a history of cholecystectomy. There
were no occurrences of severe adverse events (SAE).
Patients’ characteristics
The patients’ characteristics are shown in Table 1.
There were no statistically significant differences be-
tween the groups for all the variables measured at baseline.
All the anthropometric variables decreased significantly
from t2 to t16 (p < 0.001), PP and ITT in both groups.
Treatment with PG significantly increased (p < 0.05) reduc-
tions in both body weight and BMI (see Table 2). Treatment
in the ST+ PG group was more effective in reducing ab-
dominal circumference. However, when compared to group
ST+ PL, the changes were not statistically significant.
After about 9–10 weeks (corresponding to t11-t12) in
the ST + PL group, all the variables on the curve caused
the slope to become almost flat since no further im-
provement was detectable, whereas in the ST + PGnd of the treatment (PP): average value (SD)
MI Waist circumf.
T + PL ST + PG ST + PL ST + PG
5.0 (3.26) 35.0 (3.72) 108.3 (9.86) 110.4 (10.13)
4.7 (3.16) 34.6 (3.75) 107.5 (9.36) 108.7 (9.73)
3.4 (3.50) 32.7 (3.46) 100.9 (9.63) 101.6 (9.55)
3.4 (3.54) 32.6 (3.48) 100.9 (9.69) 101.3 (9.65)
1.6(1.18) 2.4 (1.40) 7.4 (7.66) 9.1 (6.83)
.003 0.276
.004 0.293
Table 4 Values of the anthropometric measures before and at the end of the treatment (ITT): average value (SD)
Times Body weight BMI Waist circumf.
ST + PL ST + PG ST + PL ST + PG ST + PL ST + PG
t2 99.5 (11.69) 99.8 (14.95) 35.4 (3.62) 35.1 (3.73) 109.3 (10.14) 110.9 (10.55)
t3 98.6 (11.44) 99.0 (14.69) 35.1 (3.56) 34.7 (3.75) 108.6 (9.72) 109.1 (10.20)
Changes shown as continuous variables
t15 95.6 (12.42) 94.2 (14.55) 34.0 (3.91) 33.0 (3.60) 102.7 (10.34) 102.9 (10.39)
t16 95.5 (12.43) 94.0 (14.60) 34.0 (3.94) 33.0 (3.62) 102.6 (10.40) 102.6 (10.52)
Weeks 22.9 (7.26) 23.9(5.49)
Differencet16 from t2 4.02 (2.94) 5.83 (4.09) 1.44 (1.10) 2.14 (1.48) 6.70 (7.01) 8.34 (6.73)
p U test 0.023 0.009 0.266
p t test 0.010 0.007 0.219
Table 6 Study duration and the number of 5R at the visits (ITT)
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ables was shown.
The cut-off 5R achieved during t16 (about 25 weeks)
is provided in Table 3.
The 5R target was reached by 20 subjects receiving the
ST + PL treatment (47.6 %) and by 32 subjects treated
with ST + PG (71.1 %) Tables 4, 5, and 6.
The likelihood ratio analysis indicated that a statisti-
cally significant difference (p < 0.002) was evident start-
ing from t 8, corresponding to 44–46 days of treatment.
The difference between the two groups was maintained
until the end of treatment Fig. 2.
There was a statistically significant difference between
the study groups (log-rank p = 0.001) if reaching a body
weight of 95 % of the initial body weight, measured at
the time of the visit, was considered as the time point of
achieving target weight. The median time to achieve 5R
in the ST + PG group was 56 days, whereas it was
119 days in the ST + PL group. As illustrated by the
Kaplan-Meier curve, patients who did not lose 5 % of
their initial body weight during the study period will be
recorded as censored data Fig. 3.
Discussion
The results presented in this trial show the superiority
of the concurrent treatment with PG compared to pla-
cebo. During the study period, patients received similar
intervention using the standard treatment recommendedTable 5 Study duration and the number of 5R at the visits (PP)
Control Days 5 %-Responder
cumulative
Difference




TestST + PL ST + PG ST + PL ST + PG
t3 7.1 7.7 0 0 0 -
t4 14.4 16.6 0 1 1 1.000
Changes shown as continuous variables
t15 149.5 152.0 17 31 14 0.010
t16 174.1 176.3. 20 32 12 0.030by the associations [3]. The main components of this
lifestyle intervention included making dietary changes
according to the evidence-based guidelines (level 1 nu-
tritional interventions) in combination with increased
physical activity. The PG group had a statistically signifi-
cant greater weight loss than group ST + PL.
Weight loss and mild short-term adverse effects not
requiring medical attention in both groups, confirmed
the success of this treatment. This outcome allows a
population projection.
The possible amount of weight loss that may be
achieved over a period of six months through an evidence
level 1 nutritional intervention was between 3.2 and
4.3 kg. This conclusion made by the experts of the associ-
ations [3] is similar to the data obtained from other stud-
ies [8,9]. Thus, an external validity of the data and findings
of this study is ensured, since the result achieved showed
that in the ITT population the placebo group experienced
a weight loss of 4.0 kg (CI: 3.2–4.9). The average body
weight loss of an additional 1.8 kg obtained in the ST +
PG group (weight loss of 5.8 kg, CI: 4.7–7.0) is therefore
attributable to the mechanism of action of PG.
Compare BMI ST + PG 2.14 kg/m2 (CI: 1.72–2.54) ver-
sus ST + PL 1.43 kg/m2 (CI: 1.13 – 1.74).
Compared to the 24-week clinical trials [10,11], weight













t3 12.0 (4.4) 11.2 (4.4) 0 0 0
t4 20.1 (5.0) 18.9 (5.0) 0 1 1 0.495
Changes shown as continuous variables
t15 144.4 (35.7) 139.6 (39.9) 19 32 13 0.012
t16 166.6 (44.4) 161.4 (48.0) 23 34 11 0.033
Fig. 2 Mean body weight [% with regard to t2]. The red solid line shows the % reduction in body weight of the group (PP) receiving “standard-
treatment plus placebo tablets” against weight loss and the cyan solid line in the group receiving “standard treatment plus polyglucosamine
tablets” (PP), whereas the dashed lines in the respective colors denote the progress of the ITT groups
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types of chitosan and methodology.
There is no doubt that chitosans behave differently
from the experimental and clinical point of view, de-
pending on both the molecular weight and the combin-
ation with organic acids in their formulations.
PG is a low molecular weight chitosan (LMWC) in a
fixed combination with organic acids added to avoid
the polymer chain entanglement, which tends to hide
the positive charges of the glucosamine moieties. The
main characteristic of PG is the linearity of the poly-
mer composition that allows a more efficient fat bind-
ing capacity [6,7]. This fat binding capacity allows
lipids to reach the lower intestine where they can be
used by bacteria as fuel. For this reason, the amount of
fat detectable in feces will not be in the form of a stea-
torrhea. This observation has led some authors toclaim that chitosan does not have the ability to signifi-
cantly bind fat [12].
The experimental evidence that chitosans are a large
family of compounds that can differ in their chemical
and physical properties is an old finding [13], and that
the fat binding capacity can be enhanced by the combin-
ation of chitosan with ascorbic acid is even an older one
[14]. However, most of the time, both concepts have
been completely ignored despite the possibility that they
could be variables that may improve the clinical activity
of a given compound or formula.
In clinical trials conducted in the past [15] and in re-
cent experimental studies, the main characteristics of
chitosan have not been reported [16].
In the meta-analysis conducted by Jull et al. [9] in
2009, most of the trials did not even mention the
chemico-physical specifications of chitosan.
Fig. 3 Kaplan-Meier curve estimating percentage of patients with weight loss of 5 % of initial body weight (5R)
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the authors treating overweight subjects with PG, in
combination with light physical activity [17]. The out-
come demonstrated a reduction in body weight, waist
circumference and also in the risk of developing meta-
bolic syndrome.
In the first 50 days of ST + PG treatment, 42.2 % of
the subjects showed a 5 % body weight loss compared
with 9.2 % in the ST + PL group.Achieving the goal of the clinical trial within a short
period of time is a good incentive for maintenance of body
weight since it motivates the patients to continue with the
treatment schedule and increases the patients’ confidence in
their ability to manage their body weight. This aspect is im-
portant because it encourages the patients to persevere with
treatment and achieve better results.
In the current clinical trial the daily fat restriction was
limited to 80 g instead of the usual 60 g. Long-term fat
Pokhis et al. BMC Obesity  (2015) 2:25 Page 8 of 8restriction of twenty grams more per day (limiting intake
to 60 g) can be frustrating.
A positive effect was the association between PG and a
less severe dietary fat restriction, which helped to main-
tain continuation of participation in the ST + PG group.
Despite an increase in daily fat consumption between
40–60 and 60–80 g, the combined effect of ST and PG
with a high fat-binding capacity led to an equally rapid
and satisfactory weight loss.
One further aspect that needs to be considered in rela-
tion to the PG treatment concerns the evidence that al-
most 85 % of the results was obtained between 8 and 9
weeks with an evident progressive reduction of the body
weight from 1 to 10 weeks. This suggests that in case
PG does not produce a consistent activity (5 % body
weight reduction) in the first two months of treatment,
the patient has to be considered “not sensitive” and the
intervention with PG will lose its cost-effectiveness ratio.
Conclusion
The patients that obtained the 5R cut-off with PG after
9 weeks of treatment were three times more than those
without (27 versus 9 subjects) and a consistent differ-
ence was maintained between the two groups until the
end of the trial; 34 participants achieved 5R in the ST +
PG group (64.1 %) compared to only 23 participants in
the ST + PL group (42.6 %) (ITT) (p Fisher = 0.033).
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